🔍
Search Results - inflammatory+disorders
25
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Antibodies that Enhance PAD4 Activity for the Study of Autoimmune Diseases
Value Proposition· Enhanced Research Capabilities: Provides five distinct human monoclonal antibodies that enhance PAD4 activity for in vitro and in vivo experimental assays, enabling researchers to study PAD4's function in autoimmune diseases such as rheumatoid arthritis.· Scalable Production: Utilizes commercially available immortalized...
Published: 7/24/2026
|
Inventor(s):
Felipe Andrade
,
Jing Shi
,
Antony Rosen
,
Erika Darrah
Keywords(s):
Antibodies
,
Autoimmune Diseases
,
Basic Research Biomarker
,
Discovery/Research Tools
,
Disease Indication
,
Inflammatory Disorders
,
Monoclonal Antibodies
,
Research Reagent
Category(s):
Clinical and Disease Specializations > Autoimmunity
,
Technology Classifications > Diagnostics
,
Technology Classifications > Research Tools > Antibodies
Prodrug for Immunological and Oncological Therapy
Unmet NeedApproximately 1.24 million hematological cancer cases occur each year, accounting for approximately 6% of all cancer cases (Bristol Myers Squibb). Currently, standard treatment strategies include chemotherapy, radiation therapy, and stem cell transplants. However, there exist several major drawbacks for each method. Stem cell transplants can...
Published: 7/24/2026
|
Inventor(s):
Barbara Slusher
,
Rana Rais
,
Franco D'alessio
,
Pavel Majer
,
Marcela Krecmerova
,
Srinivasan Yegnasubramanian
Keywords(s):
Blood Cancer
,
Cancers
,
Disease Indication
,
Inflammatory Disorders
,
Respiratory Infections
,
Small Molecules
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutic Substance Synthesis Method
,
Therapeutics
,
Transplants
Category(s):
Clinical and Disease Specializations > Oncology > Hematologic Malignancies
,
Clinical and Disease Specializations > Transplantation
,
Technology Classifications > Therapeutic Modalities > Small Molecules
Profiling of Interferon signaling to diagnose autoimmune disorders
Unmet Need / Invention Novelty: Diagnosing an autoimmune disease using standard laboratory tests is challenging and often requires secondary validation due to high rates of false positives and overlapping biological signatures with other diseases. There is a critical need for an improved method to detect autoimmune disease signatures in tissue collected...
Published: 7/23/2026
|
Inventor(s):
Livia Casciola-Rosen
,
Antony Rosen
,
John Hall
Keywords(s):
Autoimmune Diseases
,
Basic Research Biomarker
,
Biomarker
,
Clinical Diagnostics
,
Discovery/Research Tools
,
Disease Indication
,
In Vitro Diagnostics
,
In Vitro Research Tool
,
Inflammatory Disorders
,
Research Instrument
Category(s):
Technology Classifications > Research Tools
,
Technology Classifications > Diagnostics > Biomarkers
,
Clinical and Disease Specializations > Autoimmunity
Injectable Peptide Hydrogel for Local and Controlled Delivery of Immunosuppressive Drugs
Value Proposition· Localized Drug Delivery: Enables targeted delivery of immunosuppressive drugs directly to transplant sites or affected organs, minimizing systemic exposure.· Minimize Systemic Toxicity: Local delivery enables lower drug doses and minimizes systemic drug-associated toxicity.· Extended Drug Release: Crystallization...
Published: 7/24/2026
|
Inventor(s):
Giorgio Raimondi
,
Joel Schneider
,
Poulami Majumder
Keywords(s):
Disease Indication
,
Drug Delivery Vehicle
,
Hydrogel
,
Inflammatory Disorders
,
Therapeutic Matter
,
Therapeutics
,
Tissue/organ transplant rejection
Category(s):
Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms
Engineered Tolerogenic Artificial Antigen-presenting Cells for Specific Expansion of Regulatory T Cells
Unmet NeedGlobal incidence of autoimmune disease is on the rise, and currently one in twelve Americans (including one in 9 women) suffer from autoimmune disease. Particularly, Type 1 Diabetes (T1D) represents a highly prevalent autoimmune disease, affecting over 20 million people. These diseases occur when the body’s immune system incorrectly attacks...
Published: 7/24/2026
|
Inventor(s):
Jordan Green
,
Jamie Spangler
,
Stephany Tzeng
,
Kelly Rhodes
,
Giorgio Raimondi
,
Marcos Iglesias Lozano
,
Jakub Tomala
,
Derek VanDyke
,
Randall Meyer
Keywords(s):
Autoimmune Diseases
,
Biologics
,
Discovery/Research Tools
,
Disease Indication
,
Drug Delivery Vehicle
,
Inflammatory Disorders
,
Polymers
,
Recombinant Proteins
,
Research Reagent
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
,
Transplants
Category(s):
Clinical and Disease Specializations > Autoimmunity
,
Clinical and Disease Specializations > Transplantation
,
Clinical and Disease Specializations > Diabetes > Type 1 Diabetes
,
Technology Classifications > Therapeutic Modalities > Immunotherapies
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms
,
Technology Classifications > Research Tools
,
Technology Classifications > Therapeutic Modalities > Cell Therapies
Cationic Biodegradable Polymer Compositions of Biomimetic Particles including Artificial Antigen Presenting Cells
Unmet NeedOver the past decade, a myriad of immune cell therapies based on the infusion of allogeneic immune cells into patients have been tested and progressed in clinical applications. Despite continual advances, immune cell therapy via antigen presenting cells is relatively expensive and time consuming, so biomimetic materials have been applied to...
Published: 7/24/2026
|
Inventor(s):
Jordan Green
,
Jonathan Schneck
,
Alyssa Kosmides Galaro
,
Randall Meyer
,
John Hickey
,
Kelly Rhodes
Keywords(s):
Autoimmune Diseases
,
Biologics
,
Cancers
,
Disease Indication
,
Drug Delivery Vehicle
,
Inflammatory Disorders
,
Polymers
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
,
Whole cell
Category(s):
Technology Classifications > Therapeutic Modalities > Cell Therapies
,
Technology Classifications > Medical Devices > Regenerative Medicine
,
Technology Classifications > Therapeutic Modalities > Immunotherapies
,
Clinical and Disease Specializations > Immuno-Oncology
,
Clinical and Disease Specializations > Autoimmunity
Neuritin Impact T Cell Tolerance Induction and Maintenance and is a Target for Tumor Immunotherapy
Unmet NeedCancer immunotherapy is a therapeutic approach that has revolutionized advanced cancer treatment. In particular, the use of therapeutic blocking antibodies to cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed cell death protein (PD-1) has achieved routine clinical use in numerous indications. Despite these promising results, monotherapy...
Published: 7/24/2026
|
Inventor(s):
Drew Pardoll
,
Hong Yu
,
Joseph Barbi
,
Fan Pan
,
Charles Drake
Keywords(s):
Antibodies
,
Autoimmune Diseases
,
Biologics
,
Cancers
,
Combination
,
Disease Indication
,
Inflammatory Disorders
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
,
Therapy Type
Category(s):
Clinical and Disease Specializations > Autoimmunity
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Technology Classifications > Therapeutic Modalities > Immunotherapies
,
Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies
Targeting TSC2 S1366 (mouse, rat) S1365 (human) by gene engineering or phosphorylation to Regulate mTOR Signaling Cascades for Therapeutic Indications
Unmet NeedThe mechanistic target of rapamycin complex-1 (mTORC1) coordinates cellular processes and regulates recycling pathways in order to control cell growth and metabolic homeostasis. Additionally, in immune cells when the T-cell receptor is activated, the mTORC1 signaling pathway is also engaged and thus plays an important role in T-cell activation,...
Published: 7/24/2026
|
Inventor(s):
David Kass
,
Kristen Kokkonen
,
Brittany Dunkerly-Eyring
,
Mark Ranek
Keywords(s):
Disease Indication
,
Inflammatory Disorders
,
Target
,
Therapeutic Matter
,
Therapeutics
Category(s):
Technology Classifications > Therapeutic Modalities > Targets
Novel antibodies for cancer immunotherapy
Unmet NeedEpidemiological studies have shown that patients with scleroderma, a type of autoimmune rheumatic disease affecting the skin and connective tissues, have an increased risk of developing cancer relative to the general population. The exact etiology of scleroderma is still unknown. The Scleroderma Foundation estimates about 100,000 to 300,000...
Published: 7/24/2026
|
Inventor(s):
Ami Shah
,
Livia Casciola-Rosen
,
Antony Rosen
,
Takeru Igusa
,
Marikki Laiho
Keywords(s):
Antibodies
,
Autoimmune Diseases
,
Biologics
,
Biomarker
,
Cancers
,
Clinical Diagnostics
,
Diagnostic Biomarker
,
Disease Indication
,
In Vitro Diagnostics
,
Inflammatory Disorders
,
Risk Stratification
,
Scleroderma
,
Skin Disorders
,
Skin Fibrosis
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Oncology
,
Clinical and Disease Specializations > Autoimmunity
,
Clinical and Disease Specializations > Fibrosis
,
Clinical and Disease Specializations > Rare Diseases
,
Clinical and Disease Specializations > Inflammation
,
Clinical and Disease Specializations > Immunology
,
Technology Classifications > Diagnostics > Biomarkers
,
Technology Classifications > Diagnostics > In Vitro Diagnostics
,
Technology Classifications > Computers, Electronics & Software > Precision Medicine Tools
,
Technology Classifications > Diagnostics > Diagnostic Biomarkers
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Technology Classifications > Therapeutic Modalities > Antibodies
,
Technology Classifications > Therapeutic Modalities > Targets
,
Technology Classifications > Computers, Electronics & Software
,
Clinical and Disease Specializations > Dermatology
,
Technology Classifications > Diagnostics
,
Technology Classifications > Therapeutic Modalities
,
Clinical and Disease Specializations > Dermatology > Scleroderma
Discovery of Novel Compounds that Enhance Enteric Nervous System Function
Unmet needNecrotizing enterocolitis (NEC), a condition of newborns in which a portion of the bowel dies. NEC affects one in 1000-4000 births, or about 10% of preterm children and is associated with an overall mortality of up to 40%. NEC is thought to be caused by defective bacterial-host signaling during colonization of the intestine with bacteria,...
Published: 7/24/2026
|
Inventor(s):
David Hackam
,
Peng Lu
,
Chhinder Sodhi
,
Peter Wipf
Keywords(s):
Agonists/Promoters
,
Disease Indication
,
Inflammatory Disorders
,
Necrotizing Enterocolitis (NEC)
,
Non-novel
,
Predicted Novelty
,
Repurposed
,
Small Molecules
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Technology Classifications > Therapeutic Modalities > Small Molecules
,
Technology Classifications > Therapeutic Modalities > Repurposed Drugs
,
Clinical and Disease Specializations > Inflammation > Necrotizing Enterocolitis
1
2
3
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum